Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low-dose cytosine arabinoside therapy in a patient with acute myeloid leukemia.
Cytosine arabinoside in low dose is sometimes employed for treating acute myeloid leukaemia. We report here a case of acute myeloid leukemia, treated with low-dose cytosine arabinoside, who developed acute febrile neutrophilic dermatosis and Pneumocystis carinii pneumonia after attainment of remission. A direct effect of cytosine arabinoside on neutrophil function and an immunosuppressive potential in lower doses could be speculated.
Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
V
V
Chowdhary
S
S
Nityanand
K N
KN
Prasad
R
R
Pandey
S
S
Dabadghao
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D003561:Cytarabine / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D017809:Fatal Outcome; D005334:Fever / Q000209:etiology; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D004915:Leukemia, Erythroblastic, Acute / Q000150:complications* / Q000188:drug therapy; D008297:Male; D009504:Neutrophils / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000209:etiology*; D012131:Respiratory Insufficiency / Q000209:etiology; D016463:Sweet Syndrome / Q000209:etiology*
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine